Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan
As a result of participation in this educational activity, participants should increase their ability to:
Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.
*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.
The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:
- Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
- Planner (Faculty): Linda Grinnell-Merrick, MS, NP-BC
- Patient Presenter: David Kramer
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:
Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP
- Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
- Speaker: Eli Lilly, Janssen, Novartis, Pfizer
- Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
Faculty Presenter: Richard Martin, MD, MA
- Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly
Faculty Planner: Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi
The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.
Provider number: 030803.
This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).
CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
This activity is provided by Forefront Collaborative and AKH.